Category: Market/Novel Tech

Month: 16 Jun 2012

Issue: not yet available

Nature Medicine editorial expresses support for primary care trusts’ approach to the use of off-label Avastin for wet AMD

An editorial in the June issue of the journal Nature Medicine has voiced support for the Primary Care Trusts (PCT) of Southampton, Hampshire, The Isle of Wight and Portsmouth (SHIP) in their joint decision to encourage the use of bevacizumab (Avastin) for the treatment of age-related macular degeneration (AMD). The Nature Medicine editorial contributes to the on-going debate over the off-label use of Avastin over Lucentis, an almost identical drug approved in the US and UK for the treatment of wet AMD.

Back to previous

Related News

Gearoid Tuohy


by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 3rd, 2018 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]